Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Migraines

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    120 result(s) found for: Migraines. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2005-000244-90 Sponsor Protocol Number: IT/ALMO/01 Start Date*: 2005-03-08
    Sponsor Name:ALMIRALL PRODESFARMA
    Full Title: A randomized, prospective, cross-over, double blind, placebo-controlled multicentre study to assess the efficacy and tolerability of almotriptan 12.5 mg in the mild pain phase of Mestrual Migraine ...
    Medical condition: Treatment of migraine
    Disease: Version SOC Term Classification Code Term Level
    6.1 10027599 PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000866-38 Sponsor Protocol Number: MeFi/05/Dex-Mig/01 Start Date*: 2005-08-05
    Sponsor Name:A. MENARINI I.F.R.
    Full Title: DEXKETOPROFEN TROMETAMOL IN ATTACK THERAPY OF MIGRAINE.
    Medical condition: ATTACK THERAPY OF MIGRAINE.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10027599 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001649-38 Sponsor Protocol Number: 19379A Start Date*: 2022-06-24
    Sponsor Name:H. Lundbeck A/S
    Full Title: Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-003973-10 Sponsor Protocol Number: EU-2004-04 Start Date*: 2005-07-21
    Sponsor Name:Capnia, Inc.
    Full Title: Multi-Center, Randomized Double-Blind Study to Evaluate the Efficacy and Safety of CAP3 in the Treatment of Acute Migraine
    Medical condition: Acute migraine
    Disease: Version SOC Term Classification Code Term Level
    7.1 10027599 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004259-40 Sponsor Protocol Number: 0974-012-07 Start Date*: 2007-04-27
    Sponsor Name:Merck & Co Inc.,
    Full Title: A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027599 Migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) FR (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-004095-43 Sponsor Protocol Number: 0974-046 Start Date*: 2008-12-29
    Sponsor Name:MSD Finland Oy
    Full Title: A Phase IIa Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled, Clinical Trial to Study the Efficacy and Safety of MK-0974 Co-administered with Ibuprofen or Acetaminophen in Pa...
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027599 Migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) DE (Completed) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-000785-36 Sponsor Protocol Number: MeIn/06/Fro-pp/002 Start Date*: 2007-04-26
    Sponsor Name:Menarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg
    Full Title: A double-blind, cross-over patient preference study of frovatriptan versus rizatriptan for the acute treatment of migraine
    Medical condition: Migraine with or without aura according to the IHS criteria
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027599 Migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) GR (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019288-13 Sponsor Protocol Number: MK0974-065 Start Date*: 2010-06-24
    Sponsor Name:Merck, Sharp & Dohme B.V.
    Full Title: A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Relat...
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027599 Migraine LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed) GB (Completed) SE (Completed) DE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002348-28 Sponsor Protocol Number: 0462-083 Start Date*: 2011-06-30
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Single-Dose Pharmacokinetics of MK-0462 in Migraineurs Aged 6 to 17 Years
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005689-40 Sponsor Protocol Number: COL-MIG-302 Start Date*: 2016-10-18
    Sponsor Name:CoLucid Pharmaceuticals, Inc.
    Full Title: A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A randomized, double-blind, placebo-controlled parallel group study (SPARTAN)
    Medical condition: acute migraine
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10066635 Acute migraine LLT
    19.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    19.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    19.0 10029205 - Nervous system disorders 10027599 Migraine PT
    19.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000923-15 Sponsor Protocol Number: 20160172 Start Date*: 2018-06-14
    Sponsor Name:Amgen
    Full Title: A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine
    Medical condition: Migraine prevention
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2006-006187-35 Sponsor Protocol Number: 0974-016 Start Date*: 2007-04-10
    Sponsor Name:Laboratoires Merck Sharp & Dohme - Chibret
    Full Title: A phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK-0974 in the Acute Treatment of Migraine with or Without Aura.
    Medical condition: Acute treatment of Migraine
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027599 Migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-005285-20 Sponsor Protocol Number: M/31416/50 Start Date*: 2005-12-28
    Sponsor Name:Almirall Prodesfarma, S.A.
    Full Title: Treatment of Acute Migraine when Pain is Mild versus when Pain is Moderate to Severe: an Almotriptan Parallel, Placebo Controlled Clinical Trial “Act when mild?”
    Medical condition: Acute treatment of the headache phase of migraine attacks with or without aura
    Disease: Version SOC Term Classification Code Term Level
    7.1 10027599 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002470-27 Sponsor Protocol Number: 3101-312-002 Start Date*: 2021-05-12
    Sponsor Name:Allergan Limited
    Full Title: A PHASE 3, MULTICENTER, OPEN-LABEL 52-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH CHRONIC OR EPISODI...
    Medical condition: Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    21.1 10029205 - Nervous system disorders 10066636 Chronic migraine LLT
    22.0 10029205 - Nervous system disorders 10082019 Episodic migraine LLT
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) SE (Completed) HU (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005924-12 Sponsor Protocol Number: 19678A Start Date*: 2021-12-04
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study of Lu AG09222 for the prevention of migraine in patients with unsuccessful prior preventive treatments
    Medical condition: Prevention of migraine in patients with unsuccessful prior preventive treatments
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027603 Migraine headaches HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-002667-28 Sponsor Protocol Number: 0974-031 Start Date*: 2008-05-29
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Wi...
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027599 Migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) CZ (Completed) ES (Completed) AT (Completed) DK (Completed) FR (Completed) NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001488-51 Sponsor Protocol Number: ADX10059-201 Start Date*: 2006-08-01
    Sponsor Name:Addex Pharmaceuticals S.A.
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF THE MGLUR5 NEGATIVE ALLOSTERIC MODULATOR ADX10059 IN THE ACUTE TREATMENT OF MIGRAINE
    Medical condition: Migraine with or without aura
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027599 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001431-58 Sponsor Protocol Number: ROX-2007-01 Start Date*: 2007-09-10
    Sponsor Name:ROXRO PHARMA, Inc.
    Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Analgesic Efficacy of Ketorolac Tromethamine Administered Intranasally for the Acute Treatment of Mig...
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027599 Migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005316-28 Sponsor Protocol Number: CBGG492A2214 Start Date*: 2012-07-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, parallel group, placebo controlled, study in patients with non-chronic migraine to assess the efficacy, safety and tolerability of BID oral doses of BGG492...
    Medical condition: Non-chronic migraine with or without aura
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001707-36 Sponsor Protocol Number: 20120295 Start Date*: 2014-02-26
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention
    Medical condition: Prevention of chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10027608 Migraine, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NO (Completed) FI (Completed) DK (Completed) PL (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:28:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA